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In the United States, an increasingly
disproportionate burden of tuberculosis among the
foreign-born population has led to calls for improve-
ments in the detection and treatment of latent infec-
tion in new immigrants. Current treatment guidelines
do not take into account global differences in drug-
resistance patterns or their implications for the treat-
ment of immigrants. The use of multinational surveil-
lance systems to guide the management of latent
infection according to region-specific drug-resistance
profiles could improve the efficiency of efforts to re-





We constructed a decision-analysis model
by using a hypothetical cohort of all documented im-
migrants entering the United States from developing
nations. Region-specific drug-resistance profiles were
derived from data on 30,388 cases of infection. The
model examined the effectiveness and cost effective-
ness of four strategies: no intervention or tuberculin
skin testing followed by treatment with isoniazid, treat-
ment with rifampin, or treatment with rifampin plus




A strategy of detecting and treating latent
tuberculosis infection was cost-saving among immi-
grants from Mexico, Haiti, sub-Saharan Africa, South
Asia, and developing nations in East Asia and the Pa-
cific. This strategy was highly cost effective among im-
migrants from other developing nations. Rifampin plus
pyrazinamide was the preferred strategy for treating





For new immigrants to the United
States from developing nations, a strategy of detecting
and treating latent tuberculosis infection would lead
to substantial health and economic benefits. Because
of the high prevalence of resistance to isoniazid, treat-
ment with a rifampin-containing regimen should be
strongly considered for immigrants from Vietnam,
Haiti, and the Philippines. (N Engl J Med 2002;347:
1850-9.)
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LOBAL migration is changing the interna-





industrialized nations, immigration has be-





 In the United States,










 Tuberculosis in the foreign-born popu-
lation has been attributed largely to the importation





 Recognizing that existing public health practices
are inadequate, the Centers for Disease Control and
Prevention (CDC) and the Institute of Medicine have
both called for stronger measures to detect and treat








 health care pro-
viders are faced with the challenge of managing latent
infection in populations in which the prevalence of pri-





 Despite concern regarding the effectiveness of





guidelines currently address the variation in drug-
resistance patterns among immigrants from different
countries. Optimal treatment decisions should incor-
porate these factors, as well as information on adher-
ence to drug-treatment regimens, adverse reactions,
and costs. Because of the complexity of this decision-
making process, the American Thoracic Society and
the CDC have called for a cost-effectiveness analysis








We constructed a hypothetical cohort of all documented immi-
grants 18 years of age or older who entered the United States from
G
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developing nations during the year 2000 for use in a decision-analy-
sis model. The model was designed to assess the cost effectiveness
of screening new immigrants for latent tuberculosis infection on en-
try to the United States and to identify optimal treatment strategies
for persons with no history of active disease. Our analysis was con-
ducted in adherence to the reference-case scenario outlined by the





costs and benefits were considered from the perspective of U.S. so-
ciety, with the exception of those related to secondary transmission
of infection or directly observed therapy. Future costs and benefits




A decision-analysis model that examined four strategies in the
management of latent tuberculosis infection was constructed with
the use of DATA 3.5 (TreeAge Software). The strategies were no in-
tervention and tuberculin skin testing followed by one of three treat-
ments for those with a positive test result: 300 mg of isoniazid plus
25 mg of pyridoxine daily for nine months, 600 mg of rifampin daily
for four months, or 600 mg of rifampin plus 15 to 20 mg of pyra-
zinamide per kilogram of body weight daily for two months.
A plausible range of high and low values for each variable was used
to conduct sensitivity analyses that examined the influence of error
in the values of variables on the results of the analysis. Monte Carlo
simulations were also performed, in which values for all variables
in the model were simultaneously varied over their plausible range,
with values drawn from a probabilistically weighted triangular distri-
bution. Principal assumptions and selected variables in the model




All data for the analysis were stratified according to the immi-
grants’ origin in 13 geographically independent regions of the
world. Seven of these regions included the nations from which ap-
proximately two thirds of all persons with tuberculosis among for-
eign-born persons in the United States originate: Mexico, the Phil-










 and comprised all developing nations other than those
listed above in East Asia and the Pacific, South Asia, the Middle East
and North Africa, Eastern Europe and Central Asia, sub-Saharan




The predictive value of a positive tuberculin skin test was cal-
culated for each geographic region in the analysis. The sensitivity
and specificity of the test were estimated with the use of a 10-mm
threshold and on the assumption of prior exposure to nontuber-
culous mycobacteria or vaccination with bacille Calmette–Guérin.
The relative effect of such exposure on the specificity of the skin test









 The prevalence of tuberculosis in each region was obtained






The average number of adult immigrants entering the United
States annually from each geographic region was calculated from




 The postmigration incidence




 and the frequency of future disease





The analytic horizon of the analysis was defined as the expected
lifetime of the immigrant cohort entering the United States during
2000. This value was estimated by subtracting the median age of im-




 from the average




The cumulative lifetime risk of active tuberculosis infection was es-








, where I is the average
postmigration incidence of active tuberculosis infection among im-




T is the expected number of years




The prevalence of primary drug resistance was estimated for each
region in the analysis by stratification of cases of active infection
among foreign-born persons living in the United States according
to country of origin. The estimates were derived from data on all
cases of active infection reported to the CDC from each of the 50
states, New York City, and the District of Columbia during the five




 To approximate more accurately
the primary drug-resistance profiles of our hypothetical cohort, we
considered only foreign-born persons 18 years of age or older who
had resided in the United States for less than five years and who had
no history of active infection. A total of 9550 cases met our inclu-
sion criteria, and data on resistance to pyrazinamide were available
for 75 percent of these cases. Resistance profiles according to the
geographic region of origin are shown in Supplementary Appendix
1 (available with the full text of this article at http://www.nejm.org).
In order to enhance the geographic specificity of resistance pro-




 data on primary
resistance were also obtained from 26 nations participating in the








 between 1997 and 1999. A total of
20,838 cases were used to derive these national estimates after all
persons with a history of active infection had been excluded from
the analysis. Because pyrazinamide resistance was not reported, these
data were used only for comparative analyses of the isoniazid and
rifampin regimens. In total, 30,388 cases of infection were used to




Changes in health-related quality of life due to active tuberculosis


































The prevalence of latent infection among new immigrants reflects the prev-
alence of infection in their country of origin.
Drug-resistance patterns among new immigrants reflect resistance patterns 
observed in foreign-born persons in whom active disease develops within 
five years after entry into the United States.
Among immigrants who have latent infection on entering the United 
States, the development of active disease is due to the reactivation of in-




The treatment of latent infection provides lifelong benefit by reducing the 




The treatment of latent infection with a drug to which the infecting patho-





Among immigrants treated for latent infection with rifampin plus pyrazin-
amide, the presence of resistance to either rifampin or pyrazinamide re-
duces the effectiveness of the combined regimen by 50 percent.
Given the current U.S. immigration policy, documented immigrants have 
a negligible risk of infection with the human immunodeficiency virus at 




Deaths from active tuberculosis infection occur on average within two 
months after initial diagnosis.
Adverse drug reactions during the treatment of latent infection result in an 
unscheduled ambulatory care visit.
Immigrants from developing nations have been exposed to nontuberculous 
mycobacteria or have received bacille Calmette–Guérin before entering 
the United States.
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*The base estimate is considered the most probable value for each variable, while high and low
estimates define the plausible range of values.
†Clinic visits include the costs of laboratory tests, transportation, services of interpreters, and the
patient’s time.
‡Future costs are discounted to present value.
§Effectiveness is calculated on an intention-to-treat basis.






















































































































































































































































































































































Morbidity and mortality from active tuberculosis
infection
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values for this instrument were obtained from a panel of three in-
fectious-disease specialists with expertise in tuberculosis. Mortality
statistics for persons with active infection were obtained from the




Effectiveness of the Regimen
 
The effectiveness of each regimen was determined from clinical
trials in the medical literature
 
29-31 and was adjusted for the estimated
prevalence of drug resistance within the populations participating
in those clinical trials.30,31 We estimated this prevalence using surveil-
lance data from the medical literature,46 the CDC,47 and the WHO,9
after taking into consideration the country in which the clinical trial
was conducted, the calendar year of the trial, and the participants’
status with respect to infection with the human immunodeficiency
virus (HIV). The influence of incomplete adherence on the effec-
tiveness of treatment was incorporated into the analysis through the
use of intention-to-treat analyses.
Costs and Charges
Costs attributable to transportation, ambulatory care, services of
interpreters, laboratory tests, medications, adverse drug reactions,
hospitalization, and patients’ time were included in the analysis in
adherence to current national guidelines for the management of
latent6,48 and active49 tuberculosis infection. All transportation costs
were adjusted to account for the estimated proportion of the pop-
ulation that would be driving, using public transportation, or trav-
eling by other means, such as bicycling or walking.19
The base cost of an ambulatory care visit was estimated on the
basis of the national average Medicare reimbursement rate in 2000
for a focused medical evaluation requiring 15 minutes of a physi-
cian’s time.17 The costs of a medical interpreter26 were added for
immigrants unable to speak English fluently.4 The costs of medi-
cation were calculated from the average wholesale prices of phar-
maceuticals.16
The costs and frequency of adverse drug reactions were estimated
from the medical literature.31-36 The frequency of hepatitis attrib-
utable to the use of rifampin plus pyrazinamide was estimated on
the basis of data from clinical trials conducted in predominantly
HIV-negative populations.32-35 The projected numbers of cases of
severe hepatitis for each geographic region are given in Supple-
mentary Appendix 2 (available with the full text of this article at
http://www.nejm.org).
Hospital charges and the average length of stay for persons with
drug-induced hepatitis were estimated on the basis of data from the
Healthcare Cost and Utilization Project,23 and the Medicare Pro-
vider and Analysis Review24 was used to convert hospital charges
into costs to society. The average cost of treatment per case of active
tuberculosis infection was derived from a national study.25
The costs of patients’ time were estimated from national data on
the median salaries of foreign-born persons living in the United
States.50 Time spent in travel and receiving medical care was includ-
ed in the estimates. When applicable, medical and nonmedical costs
were adjusted to U.S. dollars for the year 2000 with use of the Con-
sumer Price Index.51
RESULTS
The total net costs, the expected number of tuber-
culosis cases, the number of quality-adjusted life-years
gained, and the cost effectiveness of each management
strategy for immigrants from each geographic region
and all developing nations are shown in Table 3. Fig-
ure 1 shows the optimal treatment regimen or regi-
mens for immigrants from various regions, both with
and without contraindications to rifampin plus pyra-
zinamide,48 according to our analysis.
Our analysis indicated that a strategy of detecting
and treating latent tuberculosis infection among im-
migrants from Mexico, Haiti, Vietnam, the Philip-
pines, China, South Korea, sub-Saharan Africa, South
Asia, and other developing nations in East Asia and the
Pacific would result in both health benefits and eco-
nomic savings. Since our model predicted that treat-
ment with rifampin would be less effective and more
expensive than treatment with rifampin plus pyrazin-
amide for all regions, rifampin monotherapy was con-
sidered a “dominated” strategy when all treatment op-
tions were available. For immigrants from Vietnam,
Haiti, and the Philippines, our model predicted that
rifampin plus pyrazinamide would be the most effec-
tive and least expensive treatment option and thus was
the preferred strategy for those regions.
Our sensitivity analyses showed that, if the effec-
tiveness of isoniazid was at least 22 percent greater
than that of rifampin plus pyrazinamide in immigrants
from Vietnam, or at least 16 percent greater in immi-
grants from Haiti or the Philippines, isoniazid would
become the preferred treatment strategy for those na-
tions. If, on the other hand, a two-month course of
rifampin plus pyrazinamide could be purchased for
less than $217, it would replace isoniazid as the pre-
ferred treatment strategy for immigrants from devel-
oping nations overall. Sensitivity analyses of other
influential variables in the model are presented in
Table 4.
Monte Carlo simulations conducted for each geo-
graphic region indicated that the treatment strategies
recommended in our analysis (Fig. 1) were dominated
in fewer than 5 percent of all trials performed, thus re-
inforcing the fact that our findings were robust with
respect to error in all variables in the model.
DISCUSSION
Our analysis indicates that a strategy of screening
immigrants from developing regions of the world for
latent tuberculosis infection at the time of their entry
into the United States could result in substantial health
and economic benefits. Our model predicts that, if
such a strategy were implemented for a single year,
approximately 9000 to 10,000 cases of active tuber-
culosis infection would be averted, and $60 million
to $90 million would be saved. Although these ben-
efits would accrue over the expected lifetime of a co-
hort of immigrants who entered the United States
during a given year, approximately half of the total
benefit would be realized within six years. Moreover,
because our analysis did not consider costs attribut-
able to directly observed therapy or to the secondary
transmission of infection, our projection of financial
savings may substantially underestimate the true ben-
efits of screening.
Our study had several limitations. Foremost was our
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TABLE 3. COST EFFECTIVENESS OF TREATMENT OF LATENT TUBERCULOSIS INFECTION ACCORDING TO 
THE PATIENT’S GEOGRAPHIC REGION OF ORIGIN.*
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inability to distinguish between documented immi-
grants and other foreign-born persons, because of the
manner in which national surveillance data are col-
lected in the United States. Since immigration status
is not a component of tuberculosis case reporting, we
were limited in our ability to identify possible differ-
ences among subgroups of foreign-born persons.
Our study was also limited by a lack of population-
level data on the hepatotoxicity of daily rifampin plus
pyrazinamide. Recent reports have aroused concern
about the safety of this regimen in HIV-negative per-
sons; however, in a recent study of 589 prison inmates,
most of whom were HIV-negative, a twice-weekly reg-
imen was well tolerated.52 In our analysis, we obtained
the most current data available from four studies that
evaluated daily doses32-35 and then broadly examined
the effects of variation in hepatotoxicity in our sensi-
tivity analysis. We also considered the possibility that
chronic viral hepatitis, which is endemic in many re-
gions of the developing world, might increase the risk
of drug-induced hepatitis. Although such an effect is
biologically plausible, observational studies of popu-
lations chronically infected with hepatitis B or hepatitis
C have not found an elevated risk with isoniazid.53,54
We assumed that cultural differences among immi-
grant groups were unrelated to adherence and thus
to the effectiveness of drug regimens. The alternative
assumption would have required us to make cultural
generalizations about adherence, which we believe
would be unethical. Moreover, if culturally appropriate
education were an integral component of the treat-
ment for latent infection in immigrants, the relevance
of potential cultural differences could be minimized.
All the data on resistance in our analysis came from
surveillance programs conducted between 1996 and
2000, raising the possibility that these data might not
reflect current global trends. National data, however,
indicate that substantial changes in the prevalence of
*QALY denotes quality-adjusted life-year. All costs are presented in U.S. dollars for the year 2000 and are rounded to
the nearest $100,000. Dominated strategies are both less effective and more expensive than their competing strategies
and thus should not be adopted. Cost-saving interventions (“Savings”) are those that result in both health benefits and
financial savings.
†Dashes indicate the reference category for the first nondominated strategy.
‡China, the Philippines, South Korea, and Vietnam are excluded.
§India is excluded.
¶Mexico and Haiti are excluded.
¿The most effective strategy is adopted for each geographic region up to an incremental cost-effectiveness ratio of
$10,000 per quality-adjusted life-year.
TABLE 3. CONTINUED.
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Figure 1. Recommended Treatment Strategies for Immigrants to the United States with Latent Tuberculosis Infection According to
Geographic Region of Origin.
Panel A shows treatment strategies for patients without contraindications to rifampin plus pyrazinamide. For patients from red ar-
eas, rifampin plus pyrazinamide is recommended. For patients from turquoise, olive, or tan areas, isoniazid or rifampin plus pyra-
zinamide is recommended. For patients from blue areas, isoniazid is recommended. Panel B shows treatment strategies for patients
for whom the use of rifampin plus pyrazinamide is contraindicated. For patients from red areas, rifampin is recommended. For
patients from turquoise, olive, or tan areas, isoniazid or rifampin is recommended. For patients from blue areas, isoniazid is rec-
ommended. Smaller nations of importance include Haiti (red in Panel A, tan in Panel B) and Latvia (olive in Panel B). The maps
were generated by using Epi Info 2000 version 1.1.2 for Windows (Centers for Disease Control and Prevention).
For patients from tan areas, rifampin plus pyrazinamide (Panel A) or rifampin alone (Panel B) should be used if there is willingness
to pay an incremental cost of $10,000 per quality-adjusted life-year gained relative to isoniazid. For patients from olive areas, rifam-
pin plus pyrazinamide (Panel A) or rifampin alone (Panel B) should be used if there is willingness to pay an incremental cost of
$25,000 per quality-adjusted life-year gained relative to isoniazid. For patients from turquoise areas, rifampin plus pyrazinamide
(Panel A) or rifampin alone (Panel B) should be used if there is willingness to pay an incremental cost of $50,000 per quality-adjusted
life-year gained relative to isoniazid. Areas associated with incremental cost-effectiveness ratios exceeding $50,000 per quality-
adjusted life-year are shown in blue.
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drug resistance were not observed in specific foreign-
born populations in the United States during a recent
five-year period.55 Moreover, future trends in drug
resistance could be addressed as new data become
available.
Because of the absence of a surveillance system for
latent tuberculosis infection in the United States, our
analysis relied on data from the WHO to estimate the
international prevalence of tuberculosis infection.39
Although it is possible that the risk of latent infection
might differ between immigrants and populations of
the countries from which they came, no studies, to
our knowledge, have specifically addressed this issue.
However, when we broadly tested the effect of un-
certainty in the prevalence of latent infection in our
sensitivity analysis, we observed similar effects in each
of the treatment groups, so that there were no chang-
es in the qualitative conclusions of our analysis.
We were also limited by a lack of data regarding the
effectiveness of rifampin plus pyrazinamide in patients
with resistance to either drug. For example, we did not
wish to exclude the possibility of benefit from rifampin
alone in the presence of isolated pyrazinamide resist-
ance, since clinical data exist to demonstrate the
benefits of rifampin monotherapy.31 Therefore, we
assumed that resistance to either drug would reduce
the effectiveness of the combined regimen by 50 per-
cent. When we tested this assumption in our sensitiv-
ity analysis, we found no effect on the rank order of
our outcomes, even if two months of rifampin alone
or of pyrazinamide alone were to provide no benefit
whatsoever.
Finally, our analysis assumed that persons with HIV
infection would be excluded from legal immigration
in accordance with current U.S. policy.15 In practice,
however, some immigrants with HIV might not be
identified by the current screening system. Since high-
er rates of HIV infection would increase the risk of
active tuberculosis, the benefits of treatment of latent
infection would only be greater if a large number of
immigrants were HIV-positive.
Our study was designed to address the increasingly
disproportionate burden of tuberculosis among for-
eign-born persons in the United States, but the chal-
lenges are similar for other industrialized nations.
Although the findings of our study regarding effec-
tiveness should be generalizable to other countries,
our economic analysis was specific to the United States.
*For drug resistance, incidence, and costs, all immigrants from all developing nations are consid-
ered collectively. Dominant strategies are both more effective and less expensive than their competing
strategies and thus should be adopted.
†The base estimates for rates of primary resistance to isoniazid, rifampin, and pyrazinamide for all
immigrants were 12.6 percent, 2.7 percent, and 2.8 percent, respectively.
‡Effectiveness is considered on an intention-to-treat basis.
§The cost has been rounded to the nearest $1,000.
TABLE 4. THRESHOLD VALUES FROM ONE-WAY SENSITIVITY ANALYSES.*
Drug resistance†
If the prevalence of resistance to isoniazid in an immigrant population is lower than 5 percent, iso-
niazid becomes the dominant treatment strategy.
If the prevalence of resistance to rifampin in an immigrant population is higher than 18 percent, iso-
niazid becomes the dominant treatment strategy.
If the prevalence of resistance to pyrazinamide in an immigrant population is higher than 17 percent, 
isoniazid becomes the dominant treatment strategy.
Effectiveness‡
If the effectiveness of isoniazid is 22 percent greater than that of rifampin plus pyrazinamide, isoniazid 
becomes the dominant treatment strategy for immigrants from Vietnam.
If the effectiveness of isoniazid is 16 percent greater than that of rifampin plus pyrazinamide, isoniazid 
becomes the dominant treatment strategy for immigrants from the Philippines and Haiti.
Incidence
If the annual incidence of active tuberculosis infection exceeds 32 cases per 100,000 persons, isoniazid 
dominates a strategy of no intervention.
If the annual incidence of active tuberculosis infection exceeds 104 cases per 100,000 persons, rifam-
pin plus pyrazinamide dominates a strategy of treatment with isoniazid.
Costs
If a two-month regimen of rifampin plus pyrazinamide can be purchased for less than $217, it dom-
inates isoniazid as a treatment strategy.
If a four-month regimen of rifampin can be purchased for less than $270, it dominates isoniazid as 
a treatment strategy.
If the costs of treating a case of active tuberculosis are greater than $70,000, rifampin plus pyrazin-
amide dominates isoniazid as a treatment strategy.§
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Future analyses, however, may be required to reflect
the screening policies, immigration patterns, and
health care systems of other nations.
The general analytic framework of our analysis
could be applied to other infectious diseases for which
heterogeneous drug-resistance patterns are important.
Use of antimicrobial agents could then be better tar-
geted to local drug-resistance patterns, thereby im-
proving effectiveness, reducing costs, and possibly de-
laying the development of drug resistance.
As we enter the 21st century, new approaches must
be developed to address the globalization of infectious
diseases.1 Although immigration policy is an integral
component of national public health,7 careful atten-
tion should be given to safeguarding the civil liberties
of new immigrants,8 and great efforts made to avoid
excessive financial or bureaucratic burdens that could
delay and impair the process of acculturation. As the
United States and other industrialized nations strive
to eliminate tuberculosis, the global forces driving this
disease — namely, poverty and HIV — remain wide-
spread. Given the growing interdependence of nations
in an increasingly globalized world, ultimate success at
eliminating tuberculosis will require nations to look
beyond their borders and attend to global disparities
in the burden of this disease.
We are indebted to Barry Brause, Barry Hartman, Michael Op-
penheim, and Kent Sepkowitz for sharing their experience and ex-
pertise in tuberculosis; and to Joseph Fins for our discussions on the
ethical issues pertaining to tuberculosis screening, civil liberties, and
public health.
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